title: [Relative dose intensity of FOLFOX4 regimen].
abstract: OBJECTIVE
  Oxaliplatin (L-OHP) is one of the key drugs against advanced, recurrent colorectal cancer, and FOLFOX4 regimen combination of l-leucovorin (l-LV)and 5-fluorouracil (5-FU)with oxaliplatin is a standard therapy in colorectal cancer. We performed a retrospective study that researched adverse events and relative dose intensity(RDI)to evaluate safety and feasibility of FOLFOX4 regimen.
  
  
  METHODS
  We administered 188 patients a FOLFOX4 regimen. To evaluate RDI, this study research dose modification and delay treatment procedure was done for 1 to 13 cycles.
  
  
  RESULTS
  RDI of oxaliplatin is 89.1% (1-4 cycles), 81.4% (4-7 cycles), 78.2% (7-10 cycles), 69.0% (10-13 cycles). The factors of RDI decrease were hematologic toxicity(leucopenia, neutropenia, thrombocytopenia), peripheral neuropathy and allergic reaction. Moreover, peripheral neuropathy and allergic reaction often require therapy to be discontinued (peripheral neuropathy: 15.2%, allergic reaction: 20.3%).
  
  
  CONCLUSIONS
  Feasibility of FOLFOX4 regimen is related to incidents of hematologic toxicity, peripheral neuropathy and allergic reaction. We should pay sufficient attention to these adverse events of FOLFOX4.
authors.affiliation: Division of Chemotherapy, The Cancer Institute Ariake Hospital.
authors.forename: Daigo
authors.initials: D
authors.lastname: Shouji
authors.forename: Satoshi
authors.initials: S
authors.lastname: Matsusaka
authors.forename: Chie
authors.initials: C
authors.lastname: Watanabe
authors.forename: Mitsukuni
authors.initials: M
authors.lastname: Suenaga
authors.forename: Eiji
authors.initials: E
authors.lastname: Shinozaki
authors.forename: Masanori
authors.initials: M
authors.lastname: Matsuda
authors.forename: Kiyotoshi
authors.initials: K
authors.lastname: Kuboki
authors.forename: Mariko
authors.initials: M
authors.lastname: Ogura
authors.forename: Takashi
authors.initials: T
authors.lastname: Ichimura
authors.forename: Chin
authors.initials: C
authors.lastname: Keisho
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Mizunuma
authors.forename: Kiyohiko
authors.initials: K
authors.lastname: Hatake
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077150:Oxaliplatin
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil